Rifampin-induced selective serotonin reuptake inhibitor withdrawal syndrome in a patient treated with sertraline.
Markowitz
J S
JS
DeVane
C L
CL
D000328:Adult; D000904:Antibiotics, Antitubercular / Q000009:adverse effects*; D001008:Anxiety Disorders / Q000097:blood / Q000139:chemically induced; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004347:Drug Interactions; D006801:Humans; D008297:Male; D012293:Rifampin / Q000009:adverse effects*; D017367:Selective Serotonin Reuptake Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D020280:Sertraline / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013375:Substance Withdrawal Syndrome / Q000097:blood / Q000209:etiology*
D000904:Antibiotics, Antitubercular; D003577:Cytochrome P-450 Enzyme System; D012293:Rifampin; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline